Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olutasidenib - Forma Therapeutics

Next Previous
Drug Profile

Olutasidenib - Forma Therapeutics

Alternative Names: FT 2102; IDH1-R132 Inhibitor FT-2102; REZLIDHIA

Latest Information Update: 26 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FORMA Therapeutics
  • Developer FORMA Therapeutics; Rigel Pharmaceuticals
  • Class Amines; Antineoplastics; Nitriles; Pyridines; Quinolines; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase II Glioma
  • Phase I/II Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 17 Nov 2025 Final efficacy data from a phase I/II FT2102-HEM-101 trial in Acute myeloid leukemia or Myelodysplastic syndrome released by Rigel Pharmaceuticals
  • 03 Nov 2025 Efficacy data from a phase I/II FT2102-HEM-101 trial in Acute myeloid leukemia or Myelodysplastic syndrome released by Rigel Pharmaceuticals
  • 21 Feb 2025 Phase-II clinical trials in Glioma (In children, In adolescents, In adults, First-line therapy, Newly diagnosed, Late-stage disease, Combination therapy) in USA (PO) (NCT06161974)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top